As cancer immunotherapy continues to benefit from novel approaches which cut
As cancer immunotherapy continues to benefit from novel approaches which cut immune brake pedals (e. adaptive immune response. TAAs are commonly released upon tumor cell death and may be subsequently processed and presented by APCs. This can be augmented by stimulating tumor cell death leading to release of TAAs and subsequent presentation by APCs while at the same time administering immunomodulators to enhance particular LY 303511 supplier steps of the process. Such an approach allows for the development of vaccines in patients themselves, thereby minimizing the resource allocation required in processing. Furthermore, this strategy can take advantage of the complete antigenic repertoire of a tumor and not be limited to a single TAA. In order to elicit a strong memory anti\tumor immune response, an vaccine should ideally be able to induce immunogenic cancer cell death, facilitate the release of LY 303511 supplier TAAs, as well as enhance antigen uptake by, and activation of, antigen\presenting cells to induce anti\tumor T cell responses that will result in systemic anti\tumor immunity. The generation of potent anti\tumor T cells at one tumor site should allow them to also attack distant tumor lesions since fully activated effector T cells do not need a costimulatory signal to kill their target cells and are less susceptible to inhibitory signals (Suresh et?al., 2001; London et?al., 2000; Gudmundsdottir et?al., 1999). Therefore, effective development of an vaccination will result in a systemic response in the setting of localized treatment similar to the abscopal effect that is described in radiation therapy and felt to be driven by a T cell response (Formenti and Demaria, 2009). One tool which can be part of vaccination, oncolytic viruses C viruses that preferentially infect and kill LY 303511 supplier cancer cells C are being explored for the treatment of various malignancies (Nemunaitis, 1999). They display either a natural or engineered tumor tropism and are able to kill tumor cells via direct and indirect mechanisms (Elsedawy and Russell, 2013; Bartlett et?al., 2013). The host immune system directly kills viral protein\expressing tumor cells, leading to regression in infected tumors. Uninfected cells are indirectly killed through cross\priming of cytotoxic T\lymphocytes (CTL) and disruption of the tumor vasculature. However, the antitumor efficacy of naturally occurring viruses has been limited, suggesting that the degree of the induced immune response depends on several factors, including the particular virus used, the LY 303511 supplier tumor burden, and the immunogenicity (Elsedawy and Russell, 2013). An LY 303511 supplier advantage of killing tumor cells with virus is their abundance of innately immunostimulatory components e.g. viral proteins and nucleic acid which have been shown to activate Toll\like receptors (TLRs) expressed on APC (Zhu et?al., 2008, 2014, 2007, 2007). Another advantage of oncolytic viruses is that they can be engineered to express transgenes which can influence the anti\tumoral immune responses. This includes (i) enhancing the cross\presentation of tumor antigens, (ii) increasing the maturation of antigen\presenting cells, especially DC, and (iii) reducing immune suppression in the tumor microenvironment. Herein, we examine pre\clinical and clinical data of vaccination strategies and their emerging role in the treatment of cancer as well as new developments in tumor immunology that will lead to ongoing translational research. 1.1. Manipulation of intratumoral myeloid cells 1.1.1. Increasing the number of APC at the tumor Rabbit Polyclonal to PDRG1 site 188.8.131.52. Autologous DC Increasing the number of effective APC within the tumor microenvironment yields greater capacity for cross presentation of TAA to CD8+ T cells,.